Michael R Gold1, Johan D Aasbo2, Mikhael F El-Chami3, Mark Niebauer4, John Herre5, Jordan M Prutkin6, Bradley P Knight7, Steven Kutalek8, Kevin Hsu9, Raul Weiss10, Eric Bass11, Michael Husby12, Timothy M Stivland12, Martin C Burke13. 1. Medical University of South Carolina, Charleston, South Carolina. Electronic address: goldmr@musc.edu. 2. ProMedica Toledo Hospital, Toledo, Ohio. 3. Emory University Hospital, Atlanta, Georgia. 4. Cleveland Clinic Foundation, Cleveland, Ohio. 5. Sentara Norfolk General Hospital, Norfolk, Virginia. 6. University of Washington Medical Center, Seattle, Washington. 7. Northwestern Memorial Hospital, Chicago, Illinois. 8. Drexel University College of Medicine, Philadelphia, Pennsylvania. 9. Novant Health Heart and Vascular Institute, Matthews, North Carolina. 10. Ohio State University, Columbus, Ohio. 11. NAMSA (Biostatistics), Minneapolis, Minnesota. 12. Boston Scientific Corporation, St. Paul, Minnesota. 13. CorVita Science Foundation, Chicago, Illinois.
Abstract
BACKGROUND: The subcutaneous implantable cardioverter-defibrillator (S-ICD) was developed to reduce short- and long-term complications associated with transvenous ICD leads. Early multicenter studies included younger patients with less left ventricular systolic dysfunction and fewer comorbidities than cohorts with traditional ICD. OBJECTIVE: The purpose of this study was to characterize patient selection and the acute performance of the S-ICD in a contemporary real-world setting. METHODS: The S-ICD Post-Approval Study is a prospective registry involving 86 US centers. Patients were enrolled if they met criteria for S-ICD implantation, passed an electrocardiogram screening test, and had a life expectancy of >1 year. Analyses of descriptive statistics, Kaplan-Meier time to event, and multivariate logistic regression were performed. RESULTS: The study includes 1637 patients who underwent S-ICD implantation. The cohort included 68.6% (1123/1637) male patients, and 13.4% (220/1636) were receiving dialysis for end-stage renal disease. The mean age was 52 ± 15 years, with a mean left ventricular ejection fraction of 32.0% ± 14.6%. Electrocardiogram screening was successful for at least 1, 2, or 3 vectors in 100%, 93.8%, and 51.4% of patients, respectively. Medical imaging (65.1%, 1065/1636) and general anesthesia (64.1%, 1048/16) were used in a majority of patients, and 52.2% (855/1637) were implanted with the 2-incision technique. Induced ventricular tachycardia/ventricular tachycardia was successfully converted in 98.7% (1394/1412) of patients. The 30-day complication-free rate was 96.2%. Predictors of complications included diabetes, younger age, and higher body mass index. CONCLUSION: Contemporary US patients with S-ICD have more comorbidities than do previous cohorts with S-ICD, but they are younger with more end-stage renal disease than do patients with transvenous ICD. Implantation success is high, and short-term complication rates are acceptable.
BACKGROUND: The subcutaneous implantable cardioverter-defibrillator (S-ICD) was developed to reduce short- and long-term complications associated with transvenous ICD leads. Early multicenter studies included younger patients with less left ventricular systolic dysfunction and fewer comorbidities than cohorts with traditional ICD. OBJECTIVE: The purpose of this study was to characterize patient selection and the acute performance of the S-ICD in a contemporary real-world setting. METHODS: The S-ICD Post-Approval Study is a prospective registry involving 86 US centers. Patients were enrolled if they met criteria for S-ICD implantation, passed an electrocardiogram screening test, and had a life expectancy of >1 year. Analyses of descriptive statistics, Kaplan-Meier time to event, and multivariate logistic regression were performed. RESULTS: The study includes 1637 patients who underwent S-ICD implantation. The cohort included 68.6% (1123/1637) male patients, and 13.4% (220/1636) were receiving dialysis for end-stage renal disease. The mean age was 52 ± 15 years, with a mean left ventricular ejection fraction of 32.0% ± 14.6%. Electrocardiogram screening was successful for at least 1, 2, or 3 vectors in 100%, 93.8%, and 51.4% of patients, respectively. Medical imaging (65.1%, 1065/1636) and general anesthesia (64.1%, 1048/16) were used in a majority of patients, and 52.2% (855/1637) were implanted with the 2-incision technique. Induced ventricular tachycardia/ventricular tachycardia was successfully converted in 98.7% (1394/1412) of patients. The 30-day complication-free rate was 96.2%. Predictors of complications included diabetes, younger age, and higher body mass index. CONCLUSION: Contemporary US patients with S-ICD have more comorbidities than do previous cohorts with S-ICD, but they are younger with more end-stage renal disease than do patients with transvenous ICD. Implantation success is high, and short-term complication rates are acceptable.
Authors: Linda Wang; Neeraj Javadekar; Ananya Rajagopalan; Nichole M Rogovoy; Kazi T Haq; Craig S Broberg; Larisa G Tereshchenko Journal: Heart Rhythm Date: 2020-05 Impact factor: 6.343
Authors: Daniel J Friedman; Craig S Parzynski; E Kevin Heist; Andrea M Russo; Joseph G Akar; James V Freeman; Jeptha P Curtis; Sana M Al-Khatib Journal: Circulation Date: 2018-02-20 Impact factor: 29.690
Authors: Markus Bettin; Dirk Dechering; Gerrit Frommeyer; Robert Larbig; Andreas Löher; Florian Reinke; Julia Köbe; Lars Eckardt Journal: Clin Res Cardiol Date: 2017-12-28 Impact factor: 5.460
Authors: Toshimasa Okabe; Adrianne Miller; Tanner Koppert; Rafael Cavalcanti; Diego Alcivar-Franco; Jemina Osei; Omar Kahaly; Muhammad R Afzal; Jaret Tyler; Steven J Kalbfleisch; Raul Weiss; Mahmoud Houmsse; Ralph S Augostini; Emile G Daoud; Michael J Andritsos; Sujatha Bhandary; Galina Dimitrova; Kasey Fiorini; Hamdy Elsayed-Awad; Antolin Flores; Leonid Gorelik; Manoj H Iyer; Samiya Saklayen; Erica Stein; Katja Turner; William Perez; John D Hummel; Michael K Essandoh Journal: J Interv Card Electrophysiol Date: 2019-12-07 Impact factor: 1.900
Authors: Jason A Thomas; Erick Andres Perez-Alday; Christopher Hamilton; Muammar M Kabir; Eugene A Park; Larisa G Tereshchenko Journal: Comput Biol Med Date: 2018-05-08 Impact factor: 4.589